Business
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types – – Company to
About this update from Alkermes Plc
[{"type":"text","content":"– ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types – \n– Company to Host Investor Webcast on June 6 at 8:00 a.m. ET – \nDUBLIN, June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. The data will be presented in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually, and in an investor webcast hosted by the company on June 6, 2022. \nThe presentations will include efficacy and safety data from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). In this study, nemvaleukin demonstrated anti-tumor activity with durable responses as monotherapy in checkpoint inhibitor (CPI)-experienced melanoma and renal cell carcinoma (RCC) patients and as combination therapy in pretreated patients across a range of difficult-to-treat tumors, including in tumor types where CPIs have had limited clinical benefit, and in CPI-experienced patients. Treatment-related adverse events (AEs) were mostly transient and manageable.\n\"The results of ARTISTRY-1 demonstrate that selectively targeting the IL-2 pathway may deliver significant clinical benefit in multiple tumor types while mitigating the hallmark toxicities associated with high-dose recombinant-IL-2,\" said Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology, University of Michigan. \"These data specifically highlight the potential clinical utility of nemvaleukin as a monotherapy and in combination with pembrolizumab in heavily pretreated patients across multiple tumor types, including in mucosal melanoma and platinum-resistant ovarian cancer.\"\n\"ARTISTRY-1 provided important data that has revealed nemvaleukin's pharmacokinetic and pharmacodynamic profile, exhibited similar monotherapy anti-tumor activity as seen with high-dose IL-2, demonstrated anti-tumor activity in combination with a CPI, and established a differentiated safety and tolerabil...